1 completed, 1 not yet recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
Follow Neuroinflammation: new trials by email Literature Review of Neuroinflammation trials Research Report on Neuroinflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan - Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild | Phase 1 | Not yet recruiting | Stony Brook University | 18 | 2026-10-01 | 2026-10-02 |
| Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer [11C]PF-06809247 - Neuroinflammation | Phase 1 | Completed | Pfizer | 7 | 2016-11-16 | 2017-04-04 |
Neuroinflammatory Diseases (2) · Cognitive Dysfunction (1) · Dementia (1) · Encephalitis (1) · Heart Failure (1)
Inflammation (2) · Nervous System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cognition Disorders (1) · Heart Diseases (1) · Mental Disorders (1) · Neurocognitive Disorders (1)
11C-PS13 (1) · sacubitril and valsartan sodium hydrate drug combination (1)
Pfizer (1) · Stony Brook University (1)
United States (2)
R21AG102953 (1)